Compare PI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PI | ELVN |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | 2011 | 2020 |
| Metric | PI | ELVN |
|---|---|---|
| Price | $172.65 | $58.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $176.38 | $43.40 |
| AVG Volume (30 Days) | 479.3K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $122,633,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $25.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $87.96 | $14.79 |
| 52 Week High | $247.06 | $62.32 |
| Indicator | PI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 62.42 |
| Support Level | $130.37 | $25.63 |
| Resistance Level | $178.87 | $62.32 |
| Average True Range (ATR) | 9.74 | 2.85 |
| MACD | 2.14 | -0.19 |
| Stochastic Oscillator | 79.35 | 64.44 |
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.